secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2022-03-22T23:59:59+00:00
Accession:  0001558370-22-004073
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q4 revenue record $10.2M (+19%), FY2021 $33.9M (+30%); guides 2022 core growth 22-25%
--------------------------------------------------------------------------------

- Record Q4 revenue $10.2M (+19% YoY); FY revenue $33.9M (+30% YoY).
- Core cell therapy revenue grew 43% in Q4, drug discovery 32%; SPL program revenue $2.5M FY.
- Net loss $4.9M Q4, $19.1M FY; EBITDA loss $4.5M Q4, $17.4M FY; stock-based comp $2.4M Q4, $8.0M FY.
- 2022 guidance: core revenue growth 22-25% YoY, SPL program revenue ~$4M.
- SPL partners now 16 covering >95 programs; potential pre-commercial milestones >$1.25B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837022004073/0001558370-22-004073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837022004073/mxct-20220322x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-004073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer